Total Funding
48
18
Total FundingPost-IPO Equity raised
Growth Score 48 in past quarter
-12 pts
Heat Score 18 in past quarter
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
184288
Mustang Bio is a clinical-stage biopharmaceutical company .
Junxia Wang: Senior Director, Analytical DevelopmentPast Role: Editas Medicine, Associate Director of Immunosafety and Bioanalytical Development- Michael S. Weiss Weiss: Chairman & Founder

Fortress Biotech
About the Company
Mustang Bio is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells. The products under development are - CD123, CD20, and CS1.
